It has been reported that a defective MMR activity results in an increased resistance of cell lines to cisplatin, but not to oxaliplatin [19], which may explain the relative efficacy of oxaliplatin in colorectal cancers that are often defective in MMR [28, 29]. The gene discussed is MRC1; the disease is colorectal cancer.